H.C. Wainwright has revised its price target for Dyne Therapeutics (DYN, Financial), reducing it from $46 to $38 while maintaining a Buy recommendation. This adjustment reflects a reassessment of the company's fiscal strategy, considering the competitive environment and ongoing pipeline progress.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Dyne Therapeutics Inc (DYN, Financial) is $49.77 with a high estimate of $66.00 and a low estimate of $30.00. The average target implies an upside of 340.63% from the current price of $11.30. More detailed estimate data can be found on the Dyne Therapeutics Inc (DYN) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, Dyne Therapeutics Inc's (DYN, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
